NRX Pharmaceuticals (NRXP) Free Cash Flow (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Free Cash Flow of -$4.3 million for Q1 2026, down 23.56% year-over-year from -$5.6 million in Q1 2025, and down 16.18% quarter-over-quarter from -$3.7 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Free Cash Flow (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Free Cash Flow for 10 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 23.56% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$14.9 million (down 42.83% YoY), while the FY2025 annual figure was -$14.1 million, down 32.56% from the prior year.
- Free Cash Flow fell to -$4.3 million in Q1 2026 per NRXP's latest filing, from -$3.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.1 million in Q4 2024 and bottomed at -$14.8 million in Q2 2022.
- Historically, Free Cash Flow has averaged -$5.3 million across 5 years, with a median of -$4.0 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 244.38% — and 2024, when it surged 67.2%.
- NRX Pharmaceuticals' Free Cash Flow stood at -$8.3 million in 2022, then surged by 61.63% to -$3.2 million in 2023, then jumped by 34.25% to -$2.1 million in 2024, then sank by 76.41% to -$3.7 million in 2025, then declined by 16.18% to -$4.3 million in 2026.
- Business Quant data shows NRXP's Free Cash Flow at -$4.3 million in Q1 2026, -$3.7 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -8.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.30 Mn |
| Mar 31, 2026 | -4.30 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -3.48 Mn |
| Mar 31, 2025 | -3.48 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | -2.31 Mn |
| Sep 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Dec 31, 2023 | -3.19 Mn |
| Dec 31, 2023 | -3.19 Mn |